i've said publicly and privately
with the (potential)
i've said publicly and privately
with the (potential) impact today on businesses
via the *internet* .. mgmts' are fools if they ignore what is posted
that would be particularly true when it comes to start ups whose sole goal early on is to access quality capital
the >> PROs' sole goal >> early on re: JBII was the cycle of $
the company itself literally meant nothing because that 99% stat
could be trotted out by rote because very few OTC stox *survive*
both sides (CON side is always *ignored* by X entity) are well represented via the vehicle of choice re: OTC stock manipulation
what is equally revealing is *reading* that SMB circa 2009 and noting when
various *efforts* re: this PRIMARY ENTITY >> get undertaken
SOP (standard operating procedure *then*) was for the PRO side of X *entity* placing a call about investing .. it was almost always done
with what mgmt believed to be restricted stock
of course the *crew* had access to a MM (and level 3) and could
get restricted stock unrestricted (TX and Minnesota if memory serves)
done via *targeted trades* to other colluding members' accounts
b4 undertaking wash trading (to give illusion of volume) and using subsets of this PRIMARY *entity* on said vehicle of choice for OTC stock manipulation
subsets could be banned/booted or jailed with little *CONsequence* to the PRIMARY entity ..
to hype (stock/co/mgmt) as needed
(or in due course to *whine* as needed)
edit >> not to be confused with *exhausted/unsophisticated retail*
who have no clue about VCs and realistic time lines
give it a few months (say Sept 2009) for theCON side of this entity to enter the equation
then another couple of months b4 the first *orchestrated* run (Dec 2009)
ironically in the fall of 2009 (b4 i'd bought my first 100 shares of JBII @ approx 1.12 in early Nov 2009) .. I was documenting another totally legit OTC co. .. and would come to discover some interesting facts over
over the course of the next 6 months ..
including but not limited to an SEC atty (name utilized by *crew* who was so outraged she forwarded on to enforcement directly herself a sequence of posts from said *site*) and the FBI who were in said CEO's office to interview about SMB *aliases* (100 were mentioned)
what was remarkable about the above info was documenting the correlating *actions* of certain PROs .. including one who totally rehabbed image .. (again this requires a lot of reading for those posts
that haven't been *scrubbed*) .. i'm talking 2006 to 2009
i realize most of us have tunnel vision about JBI .. but when one realizes
that the odds are the JB was most likely *set up* across multiple levels
who literally *worked* (as I call it until MB's >> er >> exposure) the PERFECT CRIME
what is stunningly remarkable is not only P2O's advancement from table top to flagship since 2009 >> with all the efforts active against
but the ANGST ratcheting up (literally non stop) since the dolts' settlement (last *orchestrated* run of significance) in Jan 2013
that tells me PROs' are upside down on JBII (4 years will do that)
now it's a waiting game .. and clearly risk is embedded
but my money is on P2O
zero doubts successful early adopter creates generational wealth re: this newly emerging sector
runner up won't do too badly either
4kids
Plastic2Oil, Inc. (PTOI) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Tech Job Growth Defies Corporate Layoffs Job markets in the tech world are hotter than a two-dollar pistol. Despite seeing some layoffs in tech firms, the demand for skilled tech workers is still booming. You got tech companies tightening the bolts, laying off around 14,700 folks, but here's the kicker: overall tech employment shot up with 86,000 new jobs in August....
Continue Reading
CHiQ's Big Win in the AI Game In a world where technology rarely stops spinning, CHiQ has carved its own commendable niche. Snagging the AI Home Ecosystem Brand Award at IFA 2026 in Berlin, the brand's knack for pioneering AI tech isn't just a footnote—it's the whole story. The award—enough to make your competitors green with envy—highlights how far they've come in...
Continue Reading
New Strategies for IVD Clinical Studies It's high time we addressed the tangled web of managing in vitro diagnostic (IVD) clinical studies. We're talking about walking a tightrope where sponsors have to juggle regulatory scrutiny, data integrity, and operational efficiency—all while pushing innovation. Simply put, the old ways of doing things just aren't cutting it...
Continue Reading
Reolink's Bold Move Into the Future of Home Security Amidst the hustle of Berlin's IFA 2026, Reolink dropped its latest gem: the OMVI 2i Ultra—an all-in-one security powerhouse promising to change the game for home protection junkies. As usual, Reolink's got its eyes on the prize, pushing boundaries with this latest lineup. OMVI 2i Ultra: Dual-View Revolution If you've...
Continue Reading
Actinium Pharmaceuticals Steps into the Spotlight Alright, folks, here we have Actinium Pharmaceuticals, Inc. gearing up to make some noise at the H.C. Wainwright 28th Annual Global Investment Conference. This isn't just any roadshow—it's a chance to showcase the kind of pioneering work they're doing in targeted radiotherapies. With Sandesh Seth, the Chairman, taking...
Continue Reading
Index Shuffles Stir Market Pot Changes are afoot, folks, with the movers and shakers of the market indices stepping into the spotlight. A lot is brewing with S&P Dow Jones Indices making significant switches effective September 21, 2026—right before trading heats up. You better believe it's affecting more than a couple of tickers. Who's In and Who's Out? If you’ve...
Continue Reading
When the suits start flying, folks, you know there's a mess brewing somewhere in the market. Here we are, talking about AEVEX Corp, ticker NYSE:AVEX, and they’re facing some serious heat. There's some scuttlebutt about a class action lawsuit that’s got investors clutching onto their wallets tighter than ever. If you’ve been scouring over the papers, this lawsuit is...
Continue Reading
Rho's New Game: Credit Card Payments on Invoices Ah, the wonderful world where your invoices can finally ride the plastic wave! Rho, that scrappy finance platform everyone's been chattering about, just rolled out a card payment feature. Yep, from credit cards to Google Pay, they’re letting businesses skip the usual financial hurdles and get their dough directly from...
Continue Reading
CRESYN: Urban Elegance Hits Long Island City Who doesn't want to peek under the hood when a flashy new ride rolls into town? CRESYN's newly unveiled model residence in Long Island City is just that—an invitation to get up close and personal with what modern urban living can be. Forget the blueprints and glossy renderings. This place is the real deal, giving you that...
Continue Reading
A New Way Forward in Pediatric Care When a couple of seasoned pediatricians decide it's time for something fresh, eyes and ears perk up. Enter Dr. Paul W. Chung and Dr. Jane E. Rosini, diving headfirst into a revolutionary pediatric concierge program courtesy of Concierge Choice Physicians (CCP). We're talking a substantial shake-up at Weill Cornell Medicine, aiming to...
Continue Reading
Top 5 Most Recently Viewed Articles
Analyst Insights on Humana's Q3 Earnings Expectations As Humana prepares for its upcoming earnings report, analysts are closely examining the expected performance metrics. The consensus among Wall Street experts is that Humana (NYSE: HUM) will report earnings of approximately $3.48 per share. This figure marks a notable decline of 55.3% compared to the same quarter last...
Continue Reading
Understanding Price Breakouts in Trading Price breakouts are captivating setups in the trading world. However, traders often find themselves misled when relying solely on price movements without considering essential indicators. The reality of the market is that many breakouts are merely illusions that can deceive traders unprepared for unexpected reversals. Recognizing...
Continue Reading
Unlocking Earnings Potential with Pfizer Pfizer Inc. (NYSE: PFE) has positioned itself uniquely in the healthcare sector, and as it approaches its third-quarter earnings announcement, many investors are contemplating the opportunities its stock presents. Analysts anticipate that Pfizer will report earnings around 64 cents per share, a decrease compared to $1.06 in the...
Continue Reading
The Urgent Need for Trade Protection in the Trailer Industry Undoubtedly, the American trailer industry is at a critical juncture. Recent actions by the American Trailer Manufacturers Coalition highlight the pressing need for antidumping and countervailing duties as imports of van trailers from foreign countries like China, Canada, and Mexico flood the market at unfairly...
Continue Reading
Genius Group Executes Share Buyback to Boost Investor Value Genius Group Limited (NYSE: GNS), a pioneering entity in the AI-driven education sector, has made headlines with its recent buyback of one million shares, a strategic move undertaken to reinforce shareholder confidence and value. This transaction occurred against the backdrop of a well-defined plan, allowing the...
Continue Reading